LESION QUANTIFICATION IN HUMAN CAROTID ATHEROSCLEROSIS

人类颈动脉粥样硬化病变量化

• 批准号: 6906480
• 负责人: JOEL David MORRISETT
• 金额: $ 32.34万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-07-08 至 2009-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6906480
• 关键词: artery stenosis; atherosclerotic plaque; calcification; cardiovascular disorder chemotherapy; cardiovascular disorder diagnosis; carotid artery; clinical research; computer program /software; diagnosis design /evaluation; diagnosis quality /standard; fibrosis; human subject; human therapy evaluation; image processing; magnetic resonance imaging; microarray technology; microspectrophotometry; morphometry; necrosis; noninvasive diagnosis; nuclear magnetic resonance spectroscopy; patient oriented research; statistics /biometry

DESCRIPTION (provided by applicant): Atherosclerotic lesions in the cardiovascular system range widely in severity from the limited fatty streak to the extensive complicated plaque. Between these two extremes are lesions that are especially vulnerable to disruption at their surface, often leading to thrombosis and vessel occlusion. The non-invasive detection of these lesions in vivo would provide valuable information for guiding appropriate medical and surgical intervention, as well as monitoring drug therapy over time. This project involves integrated studies on atherosclerotic lesions in human carotid arteries, vessels that afford several important experimental advantages, including availability of surgical tissue (number and mass) and relative ease of imaging in vivo. A primary objective of this project is to develop and refine in vivo MRI to a state where it can accurately quantify physical dimensions of carotid atherosclerotic lesions (e.g. residual lumen area, wall thickness, plaque area) at specific sites throughout the vessel. A secondary objective is to develop in vivo MRI to a level where it can detect, discriminate among and possibly quantify specific chemical components of lesions (e.g. calcified, lipid-rich, fibrotic, necrotic and thrombotic areas). These objectives will be pursued through three specific aims: AIM 1 is to differentiate and estimate the major components of carotid lesions based on their MR images acquired in vivo and ex vivo. Their unique combinations of T1, T2, and proton density will be identified and measured using 3D contour plots, parametric imaging, and feature space analysis. AIM 2 will be to quantify carotid lesion components by histologic and morphometric methods, using conventional and microarray tissue techniques, and to use these measures to calibrate corresponding MR images. AIM 3 is to use non-invasive in vivo MRI to monitor the effect of statin therapy on carotid atherosclerotic lesion characteristics in patients with greater than 40 percent stenosis. Data from all slices will be used to generate arterial profiles showing the volume, radial position, and linear location of the plaque. Successful execution of this project should provide valuable non-invasive technology for monitoring the efficacy of medical intervention on atherosclerotic lesions.

描述（由申请人提供）： 动脉粥样硬化病变 心血管系统的严重程度范围很广，从有限的脂肪纹到 广泛而复杂的斑块介于这两个极端之间的病变 特别容易受到表面破坏，通常会导致 血栓形成和血管闭塞。这些病变的非侵入性检测 vivo 将为指导适当的医疗和治疗提供有价值的信息 手术干预，以及随着时间的推移监测药物治疗。这 项目涉及人类颈动脉动脉粥样硬化病变的综合研究 动脉、血管提供了几个重要的实验优势， 包括手术组织的可用性（数量和质量）和相对容易程度 体内成像。该项目的主要目标是开发和 将体内 MRI 改进到可以准确量化物理量的状态 颈动脉粥样硬化病变的尺寸（例如残余管腔面积、壁 厚度、斑块面积）在整个血管的特定部位。二级 目标是将体内 MRI 发展到可以检测的水平， 区分并可能量化特定化学成分 病变（例如钙化、富含脂质、纤维化、坏死和血栓区域）。 这些目标将通过三个具体目标来实现： 目标 1 是根据颈动脉病变的主要成分来区分和估计 他们在体内和体外获得的 MR 图像。他们独特的 T1 组合， T2 和质子密度将使用 3D 等值线图进行识别和测量， 参数成像和特征空间分析。 目标 2 将使用传统和微阵列组织技术，通过组织学和形态测量方法量化颈动脉病变成分，并使用这些措施 校准相应的 MR 图像。 目标 3 是使用非侵入性体内 MRI 监测他汀类药物治疗对狭窄超过 40% 的患者颈动脉粥样硬化病变特征的影响。来自所有切片的数据将用于生成显示体积的动脉轮廓， 斑块的径向位置和线性位置。成功执行 该项目应提供有价值的非侵入性技术来监测 医学干预对动脉粥样硬化病变的疗效。

项目成果

Hyaluronan turnover and hypoxic brown adipocytic differentiation are co-localized with ossification in calcified human aortic valves.

透明质酸更新和缺氧棕色脂肪细胞分化与钙化的人主动脉瓣中的骨化共存。

• 发表时间: 2012-11-15
• 作者: Stephens, Elizabeth H;Saltarrelli Jr, Jerome G;Balaoing, Liezl R;Baggett, L Scott;Nandi, Indrajit;Anderson, Kristin M;Morrisett, Joel D;Reardon, Michael J;Simpson, Melanie A;Weigel, Paul H;Olmsted;Davis, Alan R;Grande
• 通讯作者: Grande

Magnetic Resonance Venous Volume Measurements in Peripheral Artery Disease (from ELIMIT).

外周动脉疾病的磁共振静脉容量测量（来自 ELIMIT）。

• 发表时间: 2016-11-01
• 作者: Kamran, Hassan;Nambi, Vijay;Negi, Smita;Yang, Eric Y;Chen, Changyi;Virani, Salim S;Kougias, Panos;Lumsden, Alan B;Morrisett, Joel D;Ballantyne, Christie M;Brunner, Gerd
• 通讯作者: Brunner, Gerd

Application of protein lysate microarrays to molecular marker verification and quantification.

蛋白质裂解物微阵列在分子标记验证和定量中的应用。

• 发表时间: 2005-11-10
• 影响因子: 2
• 作者: Ramaswamy, Anitha;Lin, E;Chen, Iou;Mitra, Rahul;Morrisett, Joel;Coombes, Kevin;Ju, Zhenlin;Kapoor, Mini
• 通讯作者: Kapoor, Mini

The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT).

血管内介入试验 (ELIMIT) 后脂质修饰对周围动脉疾病的影响。

• 发表时间: 2013-12
• 影响因子: 5.3
• 作者: Brunner, Gerd;Yang, Eric Y;Kumar, Anirudh;Sun, Wensheng;Virani, Salim S;Negi, Smita I;Murray, Tyler;Lin, Peter H;Hoogeveen, Ron C;Chen, Changyi;Dong, Jing;Kougias, Panagiotis;Taylor, Addison;Lumsden, Alan B;Nambi, Vijay;Ballantyne, Chri
• 通讯作者: Ballantyne, Chri

Quantification of calcification in atherosclerotic lesions.

动脉粥样硬化病变钙化的量化。

• 发表时间: 2005-08
• 作者: Higgins, Catherine L;Marvel, Seth A;Morrisett, Joel D
• 通讯作者: Morrisett, Joel D